Edwards Lifesciences (EW) Pre-announces Disappointing Revenue
Tweet
Share
E-mailGet Alerts EW Hot Sheet
Price: $89.79 -0.04%
Financial Fact:
Cost of goods sold: 201.4M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Cost of goods sold: 201.4M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Edwards Lifesciences Corporation (NYSE: EW) announced today that based on preliminary financial data, the Company estimates total sales of $448 million for the quarter ended September 30, 2012.
The consensus revenue estimates was for $476.56 million.
Transcatheter heart valve sales were below expectations for the third quarter, with global sales estimated at $124 million, including U.S. sales of $55 million.
The consensus revenue estimates was for $476.56 million.
Transcatheter heart valve sales were below expectations for the third quarter, with global sales estimated at $124 million, including U.S. sales of $55 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
- Opera Limited (OPRA) Misses Q2 EPS by 1c ; Offers Guidance
- Advance Auto Parts (AAP) Tops Q2 EPS by 22c; lifrs profit guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
